A5017279386- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
- Respiratory viral infections research
- Bacterial Identification and Susceptibility Testing
- Hepatitis B Virus Studies
- Nosocomial Infections in ICU
- Liver Disease Diagnosis and Treatment
- Antibiotic Resistance in Bacteria
- COVID-19 Clinical Research Studies
- Pneumonia and Respiratory Infections
- Antibiotic Use and Resistance
- Streptococcal Infections and Treatments
- Antimicrobial Resistance in Staphylococcus
- Long-Term Effects of COVID-19
- COVID-19 Impact on Reproduction
- Tracheal and airway disorders
- Chronic Lymphocytic Leukemia Research
- Neonatal and Maternal Infections
- Pancreatitis Pathology and Treatment
- Pharmaceutical Practices and Patient Outcomes
- Infective Endocarditis Diagnosis and Management
Hospital Universitario Son Espases
2015-2024
Health Research Institute of the Balearic Islands
2018-2023
Instituto Ramón y Cajal de Investigación Sanitaria
2020-2023
Instituto de Salud Carlos III
2023
Universitat de les Illes Balears
2023
Hospital Clínic de Barcelona
2004-2021
Hospital Universitario Ramón y Cajal
2020
Universidad de Alcalá
2020
Hospital de Cruces
2018
Hospital Universitario Son Dureta
2004-2015
Current therapies for chronic hepatitis C virus (HCV) in HIV co-infected patients have a low success rate and are poorly tolerated. We evaluated the efficacy safety of interferon alfa-2b (IFN) + ribavirin (RBV) versus pegylated (PEG-INF) RBV.Randomized, single-centre, open-label clinical trial including with: detectable HCV-RNA, alanine aminotransferase > 1.5-fold upper limit normal, abnormal liver histology, CD4 cell count 250 x 10/l RNA < 10 000 copies/ml. Patients were assigned to INF (3...
Background: Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result similar efficacy and lower plasma lipids. Methods: SPIRAL is a 48-week multicentre, open-label trial which HIV-infected adults less than 50 copies/ml of HIV RNA for at least the previous 6 months on inhibitor-based therapy were randomized (1: 1) switch from inhibitor or continue therapy. Primary endpoint was proportion free treatment failure (noncompleter = failure) 48...
Using a large multicenter prospective cohort of Pseudomonas aeruginosa bacteremia, we demonstrate that the exoU type III secretion system genotype is independently associated with increased risk early mortality bloodstream infections, whereas late multidrug-resistant profiles. Background. The (TTSS) major virulence determinant aeruginosa. objective this study was to determine whether TTSS useful prognostic marker P. bacteremia mortality. We also studied potential association between...
Background. Empirical combination therapy is recommended for patients with known or suspected Pseudomonas aeruginosa (PA) infection as a means to decrease the likelihood of administering inadequate antimicrobial treatment, prevent emergence resistance, and achieve possible additive even synergistic effect. Methods. We performed post hoc analysis PA bloodstream infections from published prospective cohort. Mortality was compared in treated adequate empirical definitive (AECT, ADCT),...
The impact of antimicrobial resistance on clinical outcomes is the subject ongoing investigations, although uncertainty remains about its contribution to mortality. We investigated carbapenem mortality in Pseudomonas aeruginosa bacteremia a prospective multicenter (10 teaching hospitals) observational study patients with monomicrobial followed up for 30 days after onset bacteremia. adjusted influence was studied by using Cox regression analysis. Of 632 episodes, 487 (77%) were caused...
We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis.
BackgroundFactors affecting outcomes of SARS-CoV-2 infection in people living with HIV are unclear. We assessed the factors associated diagnosis and severe among HIV.MethodsWe did a retrospective cohort study using data from PISCIS Catalonia (Spain) between March 1 Dec 15, 2020. linked integrated health-care, clinical, surveillance registries through Public Data Analysis for Health Research Innovation Program (PADRIS) to obtain on diagnosis, chronic comorbidities, as well clinical mortality...
The “D drug” HIV reverse-transcriptase inhibitors zalcitabine, didanosine, and stavudine are relatively strong of polymerase-gamma compared with the “non-D drugs” zidovudine, lamivudine, abacavir. D drugs deplete mitochondrial DNA (mtDNA) in cultured hepatocytes. This mtDNA depletion is associated an increased vitro production lactate. To investigate origin hyperlactatemia HIV-infected patients effects antiretroviral therapy on liver mtDNA, we biopsied tissue from 94 individuals chronic...
Although two pegylated interferons (Peg-IFN) are available to treat chronic hepatitis C virus (HCV) infection, no head-to-head comparative studies have been published. We aim compare the efficacy and safety of PEG IFN alfa-2b (PEG 2b) versus alfa-2a 2a), plus ribavirin (RBV). A prospective, randomized, multi-center, open-label clinical trial including 182 human immunodeficiency (HIV)-hepatitis patients naïve for HCV therapy was performed. Patients were assigned 2b (80-150 mug/week; n = 96)...
The antimicrobial agents are unique drugs for several reasons. First, their efficacy is higher than other in terms of reduction morbidity and mortality. Also, antibiotics the only group associated with ecological effects, because administration may contribute to emergence spread microbial resistance. Finally, they used by almost all medical specialties. Appropriate use antimicrobials very complex important advances management infectious diseases antibiotic Thus, implementation programs...
Objectives: To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r. Methods: Forty-eight weeks analysis a randomized, open-label, noninferiority trial including with virological suppression (≤200 copies/mL for ≥6 months) on LPV/r-containing triple highly active antiretroviral therapy. Patients (n = 248) were randomized 1:1 either continue LPV/r twice day 127) or switch...
Background Pulmonary abnormalities are often present in patients infected with the human immunodeficiency virus ( HIV ). Objectives The aim of study was to determine prevalence and characteristics of, risk factors for, pulmonary ‐positive patients. Methods A total 275 [mean (± standard deviation) age 48.5 ± 6.6 years] were included study, whom 95.6% had been receiving highly active antiretroviral therapy HAART ) for a mean duration 11.9 5.4 years. median (interquartile range) CD4 lymphocyte...
Objective: We analyze the factors related to progression AIDS or death in HIV-infected patients from Proyecto para la Informatización del Seguimiento Clínico epidemiológico de los pacientes con Infección por VIH/SIDA (PISCIS) Cohort and we assess optimal time initiate highly active antiretroviral therapy (HAART) taking lead into account. Methods: selected naive who were AIDS-free initiated HAART after January 1998. Statistical analyses performed using Cox proportional hazards models. Lead...
Introduction Despite the availability of new antibiotics such as daptomycin, methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia continues to be associated with high clinical failure rates. Combination therapy has been proposed an alternative improve outcomes but there is a lack studies. The study aims demonstrate that combination daptomycin plus fosfomycin achieves higher success rates in treatment MRSA than alone. Methods and analysis A multicentre open-label, randomised phase...
End-stage liver disease (ESLD) has become the main cause of mortality in patients coinfected by human immunodeficiency virus (HIV) and hepatitis B or C developed countries. The aim this study was to describe natural history prognostic factors for ESLD, with particular attention paid features affecting transplantation. This a prospective cohort 2 Spanish community-based hospitals performed between 1999 2004. One hundred four consecutive cirrhosis first clinical decompensation their chronic...
Objectives Ritonavir‐boosted atazanavir and darunavir are protease inhibitors that recommended for initial treatment of HIV infection because each has shown better lipid effects overall tolerability than ritonavir‐boosted lopinavir. The extent to which differ between treatments with whether atazanavir‐induced hyperbilirubinaemia may result in more favourable metabolic issues remain be resolved. Methods A 96‐week randomized clinical trial was carried out. primary endpoint change total...
Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.We evaluated effect tenofovir as either alafenamide/emtricitabine (TAF/FTC) or disoproxil fumarate/emtricitabine (TDF/FTC) associated clinical outcomes among people living with HIV (PLWH).We conducted a propensity score-matched analysis in prospective PISCIS cohort PLWH (n = 14 978) Catalonia, Spain. We used adjusted Cox regression models to assess association between...
The effect of heat waves on mortality is well known, but current evidence morbidity limited. Establishing the consequences these events in terms important to ensure communities and health systems can adapt them.
Coinfection with hepatitis C virus (HCV) and HIV is not uncommon therapies for both infections are currently available. A major drawback, however, could be a potentially higher risk mitochondrial toxicity (MT), defined as the elevation of pancreatic enzymes or lactate levels due to nucleoside analogue reverse transcriptase inhibitors contained in therapies.Prospective analyses clinical laboratory data, including plasma enzymes, 113 consecutive HIV/HCV-coinfected patients were assigned...
Background: Several serum markers reflecting extracellular matrix status have been correlated with liver fibrosis in non-HIV-infected patients chronic hepatitis C infection. These indexes less examined HIV/HCV-coinfected individuals. Objective: We aimed to evaluate the predictive value of for HIV-infected virus (HVC). Methods: Serum levels metalloproteinases 1 and 2 (MMP-1 -2), tissue inhibitors (TIMP-1), procollagen type III N-terminal peptide (PIIINP), hyaluronic acid (HA) were measured at...